Clinical Trials (PDQ®) - National Cancer Institute

Page Options

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?


	1-800-4-CANCER

	LiveHelp online chat

	NCI Highlights


	Maintenance Rituximab for Follicular Lymphoma Azacitidine Improves Survival in MDS Second Stem Cell Transplant Not Helpful in Myeloma

Phase III Pilot Study of Alternating Courses of MOPP and ABDV plus Radiotherapy with or without Levamisole for Advanced Hodgkin's Disease

Basic Trial Information
Objectives
Entry Criteria
Expected Enrollment
Outline
Trial Contact Information

Basic Trial Information

Phase Type Status Age Sponsor Protocol IDs
Phase III Treatment Completed no age specified MSKCC-75104

Objectives

I.  Determine if a combined chemotherapy and radiation therapy regimen 
employing 8 drugs produces a complete remission rate superior to that of MOPP 
alone.
II.  Determine if disease-free interval and/or survival is enhanced by this 
program.

Entry Criteria

Disease Characteristics:

See General Eligibility Criteria

Patient Characteristics:

See General Eligibility Criteria

General Eligibility Criteria:

Patients with advanced Stages IIB, 
IIIA, IIIB, IVA and IVB Hodgkin's disease who have had no prior treatment.

Expected Enrollment

Protocol closed and terminated 03/79.

Outline

Randomized study.
Arm I:  7-Drug Alternating Cycle Chemotherapy plus Hormone Therapy plus 
Radiotherapy.  MOPP - Nitrogen Mustard, NM, NSC-762 (or Cyclophosphamide, CTX, 
NSC-26271; or Thio-tepa, NSC-6396); Vincristine VCR, NSC-67574; Procarbazine, 
PCB, NSC-77213; Prednisone, PRED, NSC-10023; plus ABDV - Adriamycin, ADR, 
NSC-123127; Bleomycin, BLEO, NSC-125066; DTIC, NSC-45388; Vinblastine, VBL, 
NSC-49842; plus Radiotherapy to original areas of bulky nodal disease.
Arm II:  7-Drug Alternating Cycle Chemotherapy plus Hormone Therapy plus 
Radiotherapy plus Immunotherapy.  MOPP; ABDV; Radiotherapy as in Arm I; plus 
Levamisole, LEV, NSC-177023.

Trial Contact Information

Trial Lead Organizations

Memorial Sloan-Kettering Cancer Center

Ephraim Casper, MD, Protocol chair
Ph: 908-542-3000
Email: caspere@mskcc.org

Note: The purpose of most clinical trials listed in this database is to test new cancer treatments, or new methods of diagnosing, screening, or preventing cancer. Because all potentially harmful side effects are not known before a trial is conducted, dose and schedule modifications may be required for participants if they develop side effects from the treatment or test. The therapy or test described in this clinical trial is intended for use by clinical oncologists in carefully structured settings, and may not prove to be more effective than standard treatment. A responsible investigator associated with this clinical trial should be consulted before using this protocol.